Treatment of reticular and telangiectatic leg veins: Double-blind, prospective comparative trial of polidocanol and hypertonic saline

Dermatologic Surgery

Volumn 38, Issue 8, 2012, Pages 1322-1330

  Peterson, Jennifer D ^a   Goldman, Mitchel P ^a   Weiss, Robert A ^b   Duffy, David M ^c   Fabi, Sabrina G ^a   Weiss, Margaret A ^b   Guiha, Isabella ^a  

^a Goldman Butterwick Fitzpatrick and Groff Cosmetic and Laser Dermatology   (United States)

^b Maryland Skin Vein and Laser Institute   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLIDOCANOL; SODIUM CHLORIDE;

ADULT; AGED; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PAIN ASSESSMENT; PATIENT SATISFACTION; PHLEBITIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETICULAR VEIN; REVIEW; SIDE EFFECT; SKIN PIGMENTATION; TELANGIECTATIC MATTING; TELEANGIECTATIC MATTING; TREATMENT OUTCOME; ULCER; VASCULAR DISEASE; VEIN DIAMETER; VEIN TELANGIECTASIA;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEG; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; SALINE SOLUTION, HYPERTONIC; SCLEROSING SOLUTIONS; SCLEROTHERAPY; TELANGIECTASIS; VEINS;

EID: 84864631152     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2012.02422.x     Document Type: Review

References (25)

1. Weiss RA, Feied CF, Weiss M,. Vein diagnosis & treatment: a comprehensive approach. Columbus: McGraw-Hill; 2001.
2. Duffy D,. Treatment of leg veins. In:, Alam M, Silapunt S, editors. Procedures in cosmetic dermatology series (2nd ed). Burlington, MA: Saunders Elsevier Inc; 2011; pp. 65-94.
3. Duffy DM,. Sclerosants: a comparative review. Dermatol Surg 2010; 36: 1010-25.
4. Goldman MP, Guex JJ, Weiss RA,. Sclerotherapy: treatment of varicose and telangiectatic leg veins (5th ed). Philadelphia: Saunders Elsevier; 2011.
5. Goldman MP,. My sclerotherapy technique for telangiectasia and reticular veins. Dermatol Surg 2010; 36 (Suppl 2): 1040-5.
6. Nouri K,. Complications in dermatologic surgery. St. Louis: Mosby/Elsevier; 2008.
7. Conrad P, Malouf GM, Stacey MC,. The Australian polidocanol (aethoxysklerol) study. Results at 2 years. Dermatol Surg 1995; 21: 334-6.
8. Kobayashi S, Crooks S, Eckmann DM,. Dose and time dependent liquid sclerosant effects on endothelial cell death. Dermatol Surg 2006; 32: 1444-52. (Pubitemid 44934892)
9. Mol W, Furukawa H, Sasaki S, Tomaru U, et al. Evaluation of the sclero-therapeutic efficacy of ethanol, polidocanol, and OK-432 using an in vitro model. Dermatol Surg 2007; 33: 1452-9. (Pubitemid 350212681)
10. Weiss RA, Voigts R, Howell DJ,. Absence of concentration congruity in six compounded polidocanol samples obtained for leg sclerotherapy. Dermatol Surg 2011; 37: 812-15.
11. Jacquier JJ, Loretan RM,. Clinical trials of a new sclerosing agent, aethoxysklerol. Phlebologie 1969; 22: 383.
12. Guex JJ,. Indications for the sclerosing agent polidocanol. J Dermatol Surg Oncol 1993; 19: 959-61.
13. Tombari G, et al. Sclerotherapy of varices: complications and their treatment. In:, Raymond-Martimbeau P, Prescott R, Zummo M, editors. Phlebologie '92. Paris: John Libbey Eurotext; 1992. pp. 230.
14. Stricker BH, van Oijen JA, Kroon C, Ovink AH, et al. Anaphylaxis following use of polidocanol. Ned Tijdschr Geneeskd 1990; 134: 240-2.
15. Feied CF, Jackson JJ, Bren TS, Band CB, et al. Allergic reactions to polidocanol for vein sclerosis. Two case reports. J Dermatol Surg Oncol 1994; 20: 466-8. (Pubitemid 24356054)
16. Fronek H, Fronek A, Saltzberg G,. Allergic reactions to Sotradecol. J Dermatol Surg Oncol 1989; 15: 684. (Pubitemid 19172509)
17. Rabe E, Schliephake D, Otto J, Breu FX, Pannier F,. Sclerotherapy of Telangiectases and Reticular Veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulfate, and isotonic saline. Phlebology 2010; 25: 124-31.
18. Marrocco-Trischitta MM, Guerrini P, Abeni D, Stillo F,. Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation. Dermatol Surg 2002; 28: 153-5. (Pubitemid 34177355)
19. Bergan JJ, Weiss RA, Goldman MP,. Extensive tissue necrosis following high-concentration sclerotherapy for varicose veins. Dermatol Surg 2000; 26: 535-41.
20. Weiss R, Weiss M,. Resolution of pain associated with varicose and telangiectatic leg veins after compression sclerotherapy. J Dermatol Surg Oncol 1985; 11: 696.
21. Yen D, Robison DL, Tschen J,. Multiple tender, erythematous subcutaneous nodules on the lower extremities. Arch Dermatol 1993; 129: 1331. (Pubitemid 23296749)
22. Sadick NS,. Choosing the appropriate sclerosing concentration for vessel diameter. Dermatol Surg 2010; 36 (S2): 976-81.
23. Sadick N,. Hyperosmolar versus detergent sclerosing agents in sclerotherapy: effect on distal vessel obliteration. Presented at the Seventh Annual Congress of North American Society if Phlebology, Maui, HI, February1994.
24. McCoy S, Evan S, Spurrier N,. Sclerotherapy for leg telangiectasia: a blinded comparative trial of polidocanol and hypertonic saline. Dermatol Surg 1999; 25: 381.
25. Carlin MC, Ratz JL,. Treatment of telangiectasia: comparison of sclerosing agents. J Dermatol Surg Oncol 1987; 13: 1181.